Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 17.89% is 187% above its 5-year average of -20.53%, near the high end of its 5-year range (-209.87%–27.51%).
As of the fiscal period ended Tuesday, June 30, 2026. 9.39% below its 12-month average of 19.74%.
Reported quarterly EBITDA margin; no daily interpolation.
EBITDA MARGIN
17.89%
EBITDA MARGIN AVG TTM
19.74%
EBITDA MARGIN AVG 3Y
15.26%
EBITDA MARGIN AVG 5Y
-11.06%
EBITDA MARGIN AVG 10Y
-80.79%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-9.39%
CURRENT VS 3Y AVG
+17.20%
CURRENT VS 5Y AVG
+261.72%
CURRENT VS 10Y AVG
+122.14%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
TransMedics Group, Inc.
Market Cap
$2.64B
EBITDA Margin
17.89%
TTM Avg
19.74%
3Y Avg
15.26%
5Y Avg
-11.06%
Market Cap
$2.76B
EBITDA Margin
16.41%
TTM Avg
1.22%
3Y Avg
-1.65%
5Y Avg
4.31%
Market Cap
$1.26B
EBITDA Margin
3.96%
TTM Avg
-13.21%
3Y Avg
-146.19%
5Y Avg
-104.68%
Market Cap
$468.68M
EBITDA Margin
-48.80%
TTM Avg
-44.09%
3Y Avg
-45.35%
5Y Avg
-45.35%
Market Cap
$15.31M
EBITDA Margin
-114.42%
TTM Avg
-123.66%
3Y Avg
-106.79%
5Y Avg
-92.91%
Market Cap
$7.06B
EBITDA Margin
6.82%
TTM Avg
6.08%
3Y Avg
-0.44%
5Y Avg
-8.67%
Market Cap
$7.81B
EBITDA Margin
-3.14%
TTM Avg
-1.08%
3Y Avg
-5.02%
5Y Avg
-19.32%
Market Cap
$8.18B
EBITDA Margin
-11.84%
TTM Avg
-53.07%
3Y Avg
-52.51%
5Y Avg
-64.32%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| TransMedics Group, Inc. (TMDX) | $2.64B | 17.89% | 19.74% | 15.26% | -11.06% |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $2.76B | 16.41% | 1.22% | -1.65% | 4.31% |
| Teladoc Health, Inc. (TDOC)vs › | $1.26B | 3.96% | -13.21% | -146.19% | -104.68% |
| Shoulder Innovations, Inc. (SI)vs › | $468.68M | -48.80% | -44.09% | -45.35% | -45.35% |
| NRC Health (NRC)vs › | $440.37M | 21.99% | 25.40% | 28.98% | 31.97% |
| 23andMe Holding Co. (ME)vs › | $15.31M | -114.42% | -123.66% | -106.79% | -92.91% |
| Hims & Hers Health, Inc. (HIMS)vs › | $7.06B | 6.82% | 6.08% | -0.44% | -8.67% |
| Oscar Health, Inc. (OSCR)vs › | $7.81B | -3.14% | -1.08% | -5.02% | -19.32% |
| Tempus AI, Inc. (TEM)vs › | $8.18B | -11.84% | -53.07% | -52.51% | -64.32% |
| Insulet Corp. (PODD)vs › | $9.23B | 21.67% | 20.24% | 16.36% | 15.66% |
Gross Margin
58.7%
EBITDA Margin
17.9%
Operating Margin
12.2%
Net Margin
22.7%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 17.89% |
| 2026-03-31 | 14.47% |
| 2025-12-31 | 17.88% |
| 2025-09-30 | 20.96% |
| 2025-06-30 | 27.51% |
| 2025-03-31 | 23.39% |
| 2024-12-31 | 11.78% |
| 2024-09-30 | 8.37% |
| 2024-06-30 | 14.97% |
| 2024-03-31 | 17.37% |
| 2023-12-31 | 7.65% |
| 2023-09-30 | -39.80% |
| 2023-06-30 | 0.93% |
| 2023-03-31 | -1.93% |
| 2022-12-31 | -17.51% |
| 2022-09-30 | -18.12% |
| 2022-06-30 | -43.61% |
| 2022-03-31 | -55.81% |
| 2021-12-31 | -112.35% |
| 2021-09-30 | -209.87% |
| 2021-06-30 | -115.25% |
| 2021-03-31 | -85.95% |
| 2020-12-31 | -71.67% |
| 2020-09-30 | -59.34% |
| 2020-06-30 | -220.79% |
| 2020-03-31 | -101.54% |
| 2019-12-31 | -137.66% |
| 2019-09-28 | -95.91% |
| 2019-06-29 | -130.89% |
| 2019-03-30 | -122.26% |
| 2018-12-31 | -173.31% |
| 2018-09-30 | -92.25% |
| 2018-06-30 | -171.01% |
| 2018-03-31 | -183.21% |
| 2017-12-30 | -205.94% |
| 2017-09-30 | -243.92% |
| 2017-07-01 | -249.51% |
| 2017-04-01 | -293.78% |
